SAB Biotherapeutics' Immunotherapy Proposal among Top Platform Technology Solutions in WHO Report
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical development company, announced today that its DiversitAb human antibody production platform, leveraging transchromosomic cattle (Tc Bovine™), was identified as of one of the six most meritorious proposals emerging from the World Health Organization (WHO) public consultation on platform technologies for priority infectious diseases with epidemic potential.
This consultation was part of the WHO Research & Development Blueprint, a global strategy and preparedness plan that allows the rapid activation of R&D activities that can be used to save lives and avert large-scale crisis during epidemics. SAB Biotherapeutics’ technology was the only immunotherapy platform among the six finalists (of 35 proposals), which also included three vaccine platforms, a diagnostic technology and a technology covering all product streams.
In October 2015, SAB submitted their proposal, “Targeted Human Immunoglobulin to WHO Priority Pathogens Using Transchromosomic (Tc) Bovine,” which outlined a project over a two-year period to increase their response capability, leveraging a dedicated herd of human antibody producing cattle, to be readily available should an outbreak occur. When needed, the Tc Bovine could be utilized to quickly develop, test, manufacture product and submit to regulators in order to halt the outbreak and help save lives. Targeted human polyclonal immunoglobulins produced in the platform would allow for new solutions and provide an approach that is quickly scalable to be an effective global response.
The WHO sought to identify the most promising R&D platform technologies to combat their priority pathogens including Ebola and MERS, as well as other diseases with epidemic potential such as Zika and Dengue, through a multi-step evaluation process.
“Two key benefits of our unique technology platform are its ability to respond rapidly and produce potent fully-human antibodies to a wide variety of disease targets, including viruses, bacteria, and toxins, in significant quantities,” said Eddie Sullivan, Ph.D., SAB Biotherapeutics president and CEO. “In addition, we have sought to focus our efforts on pathogens including those of priority to the WHO, and have completed several successful studies targeting those potential epidemic threats.”
Proposals were evaluated by an ad hoc Advisory Group (AG) comprising world-renowned experts from medical, scientific and regulatory backgrounds–on their ability to develop and manufacture solutions for clinical trials, in months rather than years, against a variety of infectious disease threats. Other criteria included a favorable benefit-risk profile, scalability, ability to produce sufficient quantities, deliver to low- and middle-income countries (LMICs) and affordability.
The nearly yearlong evaluation included two technical workshops held in Geneva, Switzerland in April and July 2016, where the second showcased the six most “meritorious” proposals for presentation to interested WHO Member States and relevant funders that are also named in the report.
“On behalf of the Biotechnology Innovation Organization (BIO), we congratulate SAB Biotherapeutics for this significant designation by the World Health Organization (WHO),” said Jim Greenwood, BIO President and CEO. “Continued investment in research & development is critical to prevent and combat epidemics. SAB’s immunotherapy platform is just one example of how cutting-edge technologies can lead to life-saving solutions.”
SAB's proposal was presented with LFB (France), Novavax, Inc. (U.S.), United States Naval Medical Research Center, (U.S.); CSIRO Health and Biosecurity Australian Animal Health Laboratory, (Australia) in collaboration to provide vaccine technology, pre-clinical testing protocols and facilities as well as clinical expertise.
“The best way to respond to an outbreak is to prepare before it happens,” added Sullivan. “With this global recognition, we are now seeking funding so these plans can be activated and the technologies are ready–during an epidemic threat–when we need them most.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is a clinical stage, biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.
About World Health Organization
The World Health Organization (WHO) is a specialized global agency whose primary role is to direct and coordinate international health within the United Nations system. It was established on 7 April 1948 and is headquartered in Geneva, Switzerland.
SAB Biotherapeutics, Inc.
Melissa Ullerich, 605-695-8350
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom